Compare MCO & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCO | SNY |
|---|---|---|
| Founded | 1900 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.7B | 116.8B |
| IPO Year | 1998 | N/A |
| Metric | MCO | SNY |
|---|---|---|
| Price | $469.54 | $45.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 6 |
| Target Price | ★ $550.63 | $61.50 |
| AVG Volume (30 Days) | 1.8M | ★ 4.3M |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | 0.87% | ★ 3.46% |
| EPS Growth | ★ 21.40 | N/A |
| EPS | ★ 13.67 | N/A |
| Revenue | ★ $4,204,100,000.00 | N/A |
| Revenue This Year | $8.55 | $2.62 |
| Revenue Next Year | $7.72 | $6.38 |
| P/E Ratio | $34.49 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $378.71 | $44.62 |
| 52 Week High | $546.88 | $60.12 |
| Indicator | MCO | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 51.15 | 37.34 |
| Support Level | $402.28 | N/A |
| Resistance Level | $498.90 | $49.28 |
| Average True Range (ATR) | 12.82 | 0.72 |
| MACD | 5.47 | -0.18 |
| Stochastic Oscillator | 79.81 | 8.66 |
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed-income securities. The ratings segment, Moody's Investors Service, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's profit and often (depending on bond issuance levels) a majority of the firm's revenue. The other segment, Moody's Analytics, consists of decision solutions, research and insights, and data and information.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.